Seagen
SGEN
$212.15
Share price
-0.04%
Change (1 day)
21.24%
Change (1 year)
Categories
Operating Margin for Seagen (SGEN)
Operating Margin as of September 2023 (TTM): -30.69%
According to Seagen 's latest financial reports and stock price the company's current Operating Margin is -30.69%. At the end of 2022 the company had an Operating Margin of -30.69%.
Operating Margin history for Seagen from 2013 to 2012
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2022 | -30.69% | -28.49% |
| 2021 | -42.92% | -251.65% |
| 2020 | 28.30% | -263.53% |
| 2019 | -17.31% | -54.01% |
| 2018 | -37.63% | 14.21% |
| 2017 | -32.95% | -1.67% |
| 2016 | -33.51% | -6.33% |
| 2015 | -35.77% | 34.73% |
| 2014 | -26.55% | 14.36% |
| 2013 | -23.22% | -8.99% |
| 2012 | -25.51% | -83.25% |
| 2011 | -152.35% | 140.08% |
| 2010 | -63.46% | -61.14% |
| 2009 | -163.30% | -37.31% |
| 2008 | -260.49% | 4.95% |
| 2007 | -248.19% | -38.24% |
| 2006 | -401.85% | 22.26% |
| 2005 | -328.70% | -41.53% |
| 2004 | -562.13% | 22.51% |
| 2003 | -458.84% | -69.34% |
| 2002 | -1,496.48% | -82.62% |
| 2001 | -8,608.34% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 34.61% | -212.77% | 🇺🇸 USA |
 AbbVie ABBV | 18.65% | -160.77% | 🇺🇸 USA |
 Biogen BIIB | 31.30% | -201.99% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 19.24% | -162.69% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 22.54% | -173.44% | 🇬🇧 UK |
 Spectrum Pharmaceuticals
SPPI | -109.76% | 257.64% | 🇺🇸 USA |
 ImmunoGen
IMGN | -203.81% | 564.09% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | -1,520.92% | 4,855.75% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.